NRx Defense Systems, NRX Pharma unit, wins $11.18 million DARPA contract for depression treatment trial

• NRx Defense Systems, a subsidiary of NRX Pharmaceuticals, won a DARPA prime contract worth USD 11.18 million.
• Funding supports the SPARC-TMS trial combining one-day robotic neuronavigated TMS with investigational drug NRX-101 for treatment-resistant depression.
• Trial will start enrolling patients at McLean Hospital, Arizona State University, HOPE Therapeutics; leading military hospitals will join as affiliates.
• Program aims to replicate prior real-world outcomes of 91% response and 69% remission at three months using TMS with d-cycloserine.
• NRx Defense expects the study could support an FDA registration package for NRX-101 used alongside TMS in treatment-resistant depression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300700PRIMZONEFULLFEED9836687) on September 30, 2026, and is solely responsible for the information contained therein.